{"title": "Sheena Bhalla, M.D.: Internal Medicine | Lung Cancer | UT Southwestern Medical Center", "author": null, "url": "http://utswmed.org/doctors/sheena-bhalla/", "hostname": "utswmed.org", "description": "Sheena Bhalla, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center; she specializes in lung cancer.", "sitename": "Sheena Bhalla, M.D.: Internal Medicine | Lung Cancer", "date": "2016-09-11", "cleaned_text": "- Residency - Icahn School of Medicine at Mount Sinai (2015-2018), Internal Medicine - Medical School - University of Florida College of Medicine (2011-2015) - Fellowship - Icahn School of Medicine at Mount Sinai (2018-2021), Hematology Oncology Sheena Bhalla, M.D. - Internal Medicine - Hematology/Oncology - Lung Cancer - Thoracic malignancies [ New Patient Appointment ](/request-appointment/10368/sheena-bhalla/) Accepting Virtual Visits or [214-645-8300](tel:2146458300) Biography Sheena Bhalla, M.D., is an Assistant Professor in the [Department of Internal Medicine](https://utswmed.org/why-utsw/departments/internal-medicine/) at UT Southwestern Medical Center. She specializes in thoracic malignancies, including non-small cell [lung cancer](https://utswmed.org/conditions-treatments/lung-cancer/), small cell lung cancer, [mesothelioma](https://utswmed.org/conditions-treatments/mesothelioma/), and thymoma. Dr. Bhalla earned her medical degree at the University of Florida College of Medicine. She completed a residency in internal medicine at the Icahn School of Medicine at Mount Sinai, where she also gained advanced training through a hematology and medical oncology fellowship. Certified by the American Board of Internal Medicine in Medical Oncology and Hematology, she joined the UT Southwestern faculty in 2021. Dr. Bhalla is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. She has published numerous articles in her key areas of research, which include lung cancer, clinical trials, and cancer care delivery. [Education & Training](#a1) [Professional Associations & Affiliations](#a2) - American Association for Cancer Research - American Society of Clinical Oncology - International Association for the Study of Lung Cancer [Honors & Awards](#a3) - Chief Fellow, Hematology & Medical Oncology 2020-2021, Icahn School of Medicine at Mount Sinai - Student Teaching Award 2017, Icahn School of Medicine at Mount Sinai - Alpha Omega Alpha Honor Medical Society 2015 - William Osler Award in Internal Medicine 2015, University of Florida College of Medicine - Bythewood & Baker Memorial Scholarship Award for Women Medical Students 2014, University of Florida College of Medicine [Books & Publications](#a4) - Publications - [Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia.](http://www.ncbi.nlm.nih.gov/pubmed?term=30715157) Kamath V, J, 40 5 651-660 - [Admission D-dimer levels, D-dimer trends, and outcomes N, Feld J, van Gerwen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Christian K, Mascarenhas J, Dembitzer F, E, 12 196 99-105 - [Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.](http://www.ncbi.nlm.nih.gov/pubmed?term=33298722) Bhalla S, Doroshow DB, Hirsch FR, Cancer 2020 Nov/Dec 26 6 507-516 - [Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.](http://www.ncbi.nlm.nih.gov/pubmed?term=34461400) Bhalla S, Bakouny Z, Schmidt AL, Labaki C, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, Seidman D, Huang HH, Anderson-Keightly HM, El Zarif T, Abou DB, cancer 78-83 - [Impact of pathological response after neoadjuvant chemotherapy on adjuvant therapy decisions and patient outcomes in gastrointestinal cancers.](http://www.ncbi.nlm.nih.gov/pubmed?term=34032391) Bhalla S, Zhu H, Lin JY, \u00d6zbek U, Wilck EJ, Chang S, Chen X, Ward S, Harpaz N, Polydorides AD, Miller W, Fiel MI, Modica I, Fan W, Zeizafoun N, Ang C, Cancer reports (Hoboken, N.J.) 2021 May e1412 - [Impact of anticoagulation COVID-19 a score-matched study.](http://www.ncbi.nlm.nih.gov/pubmed?term=32462179) Tremblay D, van Gerwen Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh WK, Naymagon L, Blood 2020 Jul 136 1 144-147 - [Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.](http://www.ncbi.nlm.nih.gov/pubmed?term=32945149) Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, Wang B, Patel V, Jun T, Jandl T, Rahman F, Liu STH, Aberg JA, Bouvier N, Cancer medicine 2020 11 9 22 8571-8578 - [Protective role of Bruton tyrosine kinase Thibaud S, Tremblay D, Bhalla S, B, Sigel K, Gabrilove J, British journal of haematology 2020 07 190 2 e73-e76 - [Implications of Mutation Profiling in Myeloid Malignancies-PART Oncology N.Y.) 2018 05 32 5 e45-e51 - [Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients.](http://www.ncbi.nlm.nih.gov/pubmed?term=30594101) Kamath GR, Tremblay S, Najfeld V, Mascarenhas J, Taioli E, Leukemia research 2019 02 77 1-4 - [PD-L1 as a biomarker Wistuba II, Rimm DL, MS, Hirsch FR, Nature reviews. oncology 2021 06 18 6 345-362 - [Long-term follow-up for of treatment of retinitis pigmentosa with valproic acid.](http://www.ncbi.nlm.nih.gov/pubmed?term=23603755) Bhalla S, Joshi D, Bhullar S, Kasuga D, Park Y, Kay CN, The British journal of ophthalmology 2013 Jul 97 7 895-9 - [Discontinuing Tyrosine Kinase Inhibitor Therapy Bhalla S, Tremblay D, Mascarenhas J, Clinical lymphoma, myeloma & leukemia 2016 09 16 9 488-494 - [Implications of Mutation Profiling in Rampal R, Mascarenhas JO, Oncology (Williston Park, N.Y.) 2018 04 32 4 e38-e44 - [Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study.](http://www.ncbi.nlm.nih.gov/pubmed?term=33176161) Schmidt AL, Bakouny Z, Bhalla S, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, Evans M, Busser F, Wotman M, Curran CR, Zimmerman BS, Bouchard G, Jun T, Nuzzo PV, Qin Q, Hirsch L, Feld J, Kelleher KM, D, Huang HH, Anderson-Keightly HM, Choueiri Doroshow DB, Cancer cell 2020 Dec 38 6 769-770 - [Research](#a5) - Biomarker-driven clinical trials in lung cancer - Novel therapeutics and therapeutic combinations in lung cancer - Cancer care delivery Clinical Focus - Lung Cancer - Thoracic malignancies - Mesothelioma Results: 1 Locations at [Lung, Head, and Neck Cancer Clinic](/locations/cancer-care-outpatient-building/uh-cancer-ctr-lunghead-neck-cancer/) [Cancer Care Outpatient Building](/locations/cancer-care-outpatient-building/)6202 Harry Hines Blvd., 9th Floor Dallas, Texas 75235 [(214) 645-4673](tel:(214) 645-4673) [Directions to Lung, Head, and Neck Cancer Clinic](https://www.google.com/maps/search/?api=1&query=Cancer+Care+Outpatient+Building+6202+Harry+Hines+Blvd.+Dallas+Texas+75235) [Parking Info for Lung, Head, "}